Woodstock Corp Sells 743 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Woodstock Corp lowered its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 2.9% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 24,537 shares of the company's stock after selling 743 shares during the quarter. Woodstock Corp's holdings in IDEXX Laboratories were worth $10,304,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the business. Hurley Capital LLC acquired a new stake in IDEXX Laboratories during the 4th quarter worth approximately $29,000. Rialto Wealth Management LLC acquired a new stake in shares of IDEXX Laboratories in the 4th quarter valued at approximately $30,000. Colonial Trust Co SC lifted its holdings in shares of IDEXX Laboratories by 84.8% in the 4th quarter. Colonial Trust Co SC now owns 85 shares of the company's stock valued at $35,000 after buying an additional 39 shares during the period. Kestra Investment Management LLC acquired a new stake in shares of IDEXX Laboratories in the 4th quarter valued at approximately $38,000. Finally, Itau Unibanco Holding S.A. increased its stake in IDEXX Laboratories by 540.0% in the 4th quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company's stock valued at $40,000 after purchasing an additional 81 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

Insiders Place Their Bets

In other news, Director M Anne Szostak sold 1,260 shares of the company's stock in a transaction on Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total value of $645,548.40. Following the transaction, the director now directly owns 1,801 shares of the company's stock, valued at approximately $922,724.34. This represents a 41.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.98% of the stock is currently owned by insiders.

IDEXX Laboratories Trading Down 0.3%

IDEXX Laboratories stock traded down $1.45 during midday trading on Thursday, reaching $523.41. The stock had a trading volume of 164,950 shares, compared to its average volume of 649,550. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $530.73. The stock has a market capitalization of $42.09 billion, a PE ratio of 49.05, a price-to-earnings-growth ratio of 3.41 and a beta of 1.52. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. The stock's 50-day simple moving average is $455.99 and its 200 day simple moving average is $439.27.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported $2.96 EPS for the quarter, topping analysts' consensus estimates of $2.93 by $0.03. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The company had revenue of $998.43 million for the quarter, compared to analysts' expectations of $998.25 million. During the same quarter in the previous year, the firm posted $2.71 earnings per share. The firm's quarterly revenue was up 3.6% on a year-over-year basis. Analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Morgan Stanley raised their price objective on IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a research note on Monday, May 5th. Stifel Nicolaus raised their price objective on IDEXX Laboratories from $460.00 to $510.00 and gave the company a "hold" rating in a research note on Monday, May 19th. Piper Sandler raised their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research note on Monday, February 10th. Finally, Wall Street Zen downgraded IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Friday, May 30th. Four research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $536.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.